Morgan Stanley
KALA icon

Morgan Stanley’s KALA BIO KALA Stock Holding History

Morgan Stanley’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$509 Buy
59
+47
+392% +$994 ﹤0.01% 7613
2025
Q4 		$338 Sell
12
-19
-61% -$851 ﹤0.01% 7571
2025
Q3 		$2.35K Buy
31
+12
+63% +$5.95K ﹤0.01% 7273
2025
Q2 		$4.63K Hold
19
– – ﹤0.01% 7057
2025
Q1 		$5.57K Hold
19
– – ﹤0.01% 6963
2024
Q4 		$6.75K Sell
19
-1
-5% -$315 ﹤0.01% 6924
2024
Q3 		$5.67K Hold
20
– – ﹤0.01% 6877
2024
Q2 		$7.2K Sell
20
-7
-26% -$2.31K ﹤0.01% 6767
2024
Q1 		$10.8K Sell
27
-38
-58% -$14.1K ﹤0.01% 6671
2023
Q4 		$22.7K Buy
65
+32
+97% +$11.3K ﹤0.01% 6619
2023
Q3 		$14.7K Hold
33
– – ﹤0.01% 6580
2023
Q2 		$24.1K Buy
33
+2
+6% +$1.55K ﹤0.01% 6504
2023
Q1 		$23.4K Sell
31
-11
-26% -$9.6K ﹤0.01% 6567
2022
Q4 		$79.9K Buy
42
+1
+2% +$396 ﹤0.01% 6082
2022
Q3 		$23K Sell
41
-8
-16% -$6.28K ﹤0.01% 6732
2022
Q2 		$37K Sell
49
-12
-20% -$18.8K ﹤0.01% 6746
2022
Q1 		$210K Sell
61
-25
-29% -$65.5K ﹤0.01% 5893
2021
Q4 		$260K Sell
86
-37
-30% -$172K ﹤0.01% 5925
2021
Q3 		$802K Buy
123
+34
+38% +$293K ﹤0.01% 5193
2021
Q2 		$1.18M Buy
89
+46
+107% +$723K ﹤0.01% 4983
2021
Q1 		$721K Sell
43
-13
-23% -$254K ﹤0.01% 4938
2020
Q4 		$946K Buy
56
+23
+70% +$433K ﹤0.01% 4701
2020
Q3 		$622K Buy
33
+6
+22% +$138K ﹤0.01% 4531
2020
Q2 		$711K Buy
27
+24
+800% +$680K ﹤0.01% 4404
2020
Q1 		$55K Sell
3
-9
-75% -$144K ﹤0.01% 5431
2019
Q4 		$110K Buy
12
+9
+300% +$86.9K ﹤0.01% 5626
2019
Q3 		$26K Buy
3
+2
+200% +$24.3K ﹤0.01% 5936
2019
Q2 		$8K Sell
1
-1
-50% -$16.6K ﹤0.01% 6190
2019
Q1 		$37K Sell
2
-9
-82% -$160K ﹤0.01% 5795
2018
Q4 		$139K Buy
11
+3
+38% +$52K ﹤0.01% 5428
2018
Q3 		$190K Sell
8
-4
-33% -$122K ﹤0.01% 5479
2018
Q2 		$417K Sell
12
-1
-8% -$38.4K ﹤0.01% 5215
2018
Q1 		$507K Buy
13
+7
+117% +$266K ﹤0.01% 4996
2017
Q4 		$295K Buy
6
+2
+50% +$93.6K ﹤0.01% 5261
2017
Q3 		$239K Buy
+4
New +$219K ﹤0.01% 5263

Other funds holding KALA

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley's KALA Position: Q1 2026 in Review

Morgan Stanley increased its KALA BIO (KALA) stake by 392% in Q1 2026, buying an estimated $994 and bringing the position to 59 shares worth $509. The position accounts for ﹤0.01% of the portfolio, ranked #7613.

Morgan Stanley first reported a position in KALA in Q3 2017 and has held it in 35 quarters since. The position peaked at $1.18M in Q2 2021. 28 funds tracked by Wall St. Rank hold KALA as of Q1 2026.

  • Morgan Stanley held 59 shares of KALA BIO worth $509 as of Q1 2026.
  • Morgan Stanley bought 47 KALA BIO shares in Q1 2026, an estimated $994.
  • KALA BIO made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7613 holding.
  • Morgan Stanley first reported a position in KALA BIO in Q3 2017 and has held it in 35 quarters since.
  • Morgan Stanley's KALA BIO position peaked at $1.18M in Q2 2021.
  • 28 funds tracked by Wall St. Rank held KALA BIO as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.